1: S2k-Leitline Diagnostik und Therapie des kutanen Lupus erythematodes (Stand: 25.03.2020)
2: Moghadam-Kia S et al. Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients. Arch Dermatol. 2009 Mar;145(3):255-60. DOI: 10.1001/archdermatol.2008.594.
3: Zhao M et al. State of current management of the heightened risk for atherosclerotic cardiovascular events in an established cohort of patients with lupus erythematosus. Lupus Sci Med. 2023;10:e000908. DOI:10.1136/lupus-2023-000908
4: Chasset F et al. Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus. J Am Acad Dermatol. 2023 Jul;89(1):171-173. DOI: 10.1016/j.jaad.2023.02.044.
5: Werth VP et al. Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus. N Engl J Med. 2022 Jul 28;387(4):321-331. DOI: 10.1056/NEJMoa2118024.
6: Karnell JL et al. Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus. Sci Transl Med. 2021 May 26;13(595):eabf8442. DOI: 10.1126/scitranslmed.abf8442.
7: Morand E et al. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2023 Feb;75(2):242-252. DOI: 10.1002/art.42391.
